Yuping Li1,2, Jun Zhang3, Haili Wang4, Lei Zhu1, Hengzhu Zhang2, Qiang Ma1, Xiaoguang Liu1, Lun Dong1,2, Guangyu Lu5. 1. Neuro Intensive Care Unit, Department of Neurosurgery, Clinical Medical College, Yangzhou University, Yangzhou, China. 2. Department of Neurosurgery, Yangzhou Clinical Medical College of Xuzhou Medical University, Xuzhou, China. 3. Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China. 4. Department of Clinical Medicine, Dalian Medical University, Dalian Liaoning, China. 5. Institute of Public Health, Medical College, Yangzhou University, Yangzhou, China. Guangyu.lu@yzu.edu.cn.
Abstract
OBJECTIVE: The aim of this meta-analysis was to review the scientific literature published until April 18, 2021, to summarize existing knowledge on the efficacy and safety of erythropoietin (EPO) for traumatic brain injury (TBI). METHODS: This systematic review followed PRISMA guidelines. Randomized controlled trials (RCTs) reporting on the efficacy and safety of EPO in the treatment of TBI were systematically searched in relevant electronic databases according to a pre-designed search strategy. The primary outcomes are the mortality; and secondary outcomes are the good functional outcome (GFO) and adverse events (AEs). RESULTS: A total of 10 RCTs involving 2,402 participants fulfilled the inclusion criteria. The results showed that there is a significant difference in terms of the mortality (RR = 0.67, 95% CI = 0.54-0.84, P = 0.0003) and seizure rate (RR = 0.52, 95% CI = 0.29-0.96, P = 0.04) between the EPO groups compared to those in the control groups. However, compared with the control groups, the GFO in the EPO groups was not statistically significant (RR = 1.18, 95% CI = 0.93-1.48, P = 0.17). CONCLUSIONS: Findings of the present meta-analysis suggest that the use of EPO could reduce mortality rate in patients with TBI, without increasing the incidence of AEs. EPO has potential research and application value in the treatment of TBI.
OBJECTIVE: The aim of this meta-analysis was to review the scientific literature published until April 18, 2021, to summarize existing knowledge on the efficacy and safety of erythropoietin (EPO) for traumatic brain injury (TBI). METHODS: This systematic review followed PRISMA guidelines. Randomized controlled trials (RCTs) reporting on the efficacy and safety of EPO in the treatment of TBI were systematically searched in relevant electronic databases according to a pre-designed search strategy. The primary outcomes are the mortality; and secondary outcomes are the good functional outcome (GFO) and adverse events (AEs). RESULTS: A total of 10 RCTs involving 2,402 participants fulfilled the inclusion criteria. The results showed that there is a significant difference in terms of the mortality (RR = 0.67, 95% CI = 0.54-0.84, P = 0.0003) and seizure rate (RR = 0.52, 95% CI = 0.29-0.96, P = 0.04) between the EPO groups compared to those in the control groups. However, compared with the control groups, the GFO in the EPO groups was not statistically significant (RR = 1.18, 95% CI = 0.93-1.48, P = 0.17). CONCLUSIONS: Findings of the present meta-analysis suggest that the use of EPO could reduce mortality rate in patients with TBI, without increasing the incidence of AEs. EPO has potential research and application value in the treatment of TBI.
Authors: Linda Papa; Linnet Akinyi; Ming Cheng Liu; Jose A Pineda; Joseph J Tepas; Monika W Oli; Wenrong Zheng; Gillian Robinson; Steven A Robicsek; Andrea Gabrielli; Shelley C Heaton; H Julia Hannay; Jason A Demery; Gretchen M Brophy; Joe Layon; Claudia S Robertson; Ronald L Hayes; Kevin K W Wang Journal: Crit Care Med Date: 2010-01 Impact factor: 7.598
Authors: A Taylor; W Butt; J Rosenfeld; F Shann; M Ditchfield; E Lewis; G Klug; D Wallace; R Henning; J Tibballs Journal: Childs Nerv Syst Date: 2001-02 Impact factor: 1.475
Authors: Andrew I R Maas; David K Menon; P David Adelson; Nada Andelic; Michael J Bell; Antonio Belli; Peter Bragge; Alexandra Brazinova; András Büki; Randall M Chesnut; Giuseppe Citerio; Mark Coburn; D Jamie Cooper; A Tamara Crowder; Endre Czeiter; Marek Czosnyka; Ramon Diaz-Arrastia; Jens P Dreier; Ann-Christine Duhaime; Ari Ercole; Thomas A van Essen; Valery L Feigin; Guoyi Gao; Joseph Giacino; Laura E Gonzalez-Lara; Russell L Gruen; Deepak Gupta; Jed A Hartings; Sean Hill; Ji-Yao Jiang; Naomi Ketharanathan; Erwin J O Kompanje; Linda Lanyon; Steven Laureys; Fiona Lecky; Harvey Levin; Hester F Lingsma; Marc Maegele; Marek Majdan; Geoffrey Manley; Jill Marsteller; Luciana Mascia; Charles McFadyen; Stefania Mondello; Virginia Newcombe; Aarno Palotie; Paul M Parizel; Wilco Peul; James Piercy; Suzanne Polinder; Louis Puybasset; Todd E Rasmussen; Rolf Rossaint; Peter Smielewski; Jeannette Söderberg; Simon J Stanworth; Murray B Stein; Nicole von Steinbüchel; William Stewart; Ewout W Steyerberg; Nino Stocchetti; Anneliese Synnot; Braden Te Ao; Olli Tenovuo; Alice Theadom; Dick Tibboel; Walter Videtta; Kevin K W Wang; W Huw Williams; Lindsay Wilson; Kristine Yaffe Journal: Lancet Neurol Date: 2017-11-06 Impact factor: 44.182
Authors: David P Steensma; Shaker R Dakhil; Paul J Novotny; Jeff A Sloan; David B Johnson; Daniel M Anderson; Bassam I Mattar; Dennis F Moore; Daniel Nikcevich; Charles L Loprinzi Journal: Am J Hematol Date: 2015-08-14 Impact factor: 10.047
Authors: Gaby Franschman; Saskia M Peerdeman; Teuntje M J C Andriessen; Sjoerd Greuters; Annelies E Toor; Pieter E Vos; Fred C Bakker; Stephan A Loer; Christa Boer Journal: J Trauma Date: 2011-10